AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (2.5 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Current Status and Progress of Specific Laboratory Examination Methods of Active Tuberculosis Infection Diagnosis

Xuyang Chen1Kan Wang2,3( )Hongying Li1Lixin Hong1Jinghua He1( )
Outpatient Department, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510280, China
Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China
Shanghai Engineering Research Center for Intelligent diagnosis and treatment instrument, Shanghai 200240, China
Show Author Information

Abstract

Active tuberculosis infection is a major health concern in the world. Each year, millions of people die of tuberculosis, especially in third-world countries. Though the World Health Organization has recently reported the rate of mortality by this disease is declining by 3% yearly, active tuberculosis infection is still endangering human health seriously. In addition, there are many people who have a latent tuberculosis infection, and these people do not seek treatment because they have no clinical symptoms. It is true that current specific laboratory examination approaches are capable of diagnosing active tuberculosis infection promptly and accurately. But sensitivity and specificity of current diagnostic approaches are at a low level. However, the development of new nanomaterials allows more scientists to combine diagnostic methods with nanotechnology. Recently, a novel Nanodisk mass spectrometry method has been reported. Mycobacterium tuberculosis-specific peptides are enriched using an antibody-conjugated nanodisk, allowing for rapid, quantitative detection of the serum-specific antigen for active tuberculosis infection. This method overcomes the shortcomings of poor sensitivity and long turnaround time associated with current diagnostic approaches. This review discusses the current status and progress of specific laboratory examination methods of active tuberculosis diagnosis and compares the newest diagnostic techniques.

References

[1]

A. Gonzalez-Garcia, J. Fortun, E. Elorza Navas, et al., The changing epidemiology of tuberculosis in a Spanish tertiary hospital (1995-2013). Medicine (Baltimore), 2017, 96: e7219.

[2]

R. Shegokar, L. Al Shaal, and K. Mitri, Present status of nanoparticle research for treatment of tuberculosis. J Pharm Pharm Sci, 2011, 14: 100-116.

[3]

C. Seshadri, N. Sedaghat, M. Campo, et al., Transcriptional networks are associated with resistance to Mycobacterium tuberculosis infection. PLoS One, 2017, 12: e0175844.

[4]

R.M. Houben, P.J. Dodd, The global burden of latent tuberculosis infection: A re-estimation using mathematical modelling. PLOS Medicine, 2016, 13: e1002152.

[5]

H. Getahun, A. Matteelli, R.E. Chaisson, et al., Latent Mycobacterium tuberculosis infection. N Engl J Med, 2015, 372: 2127-2135.

[6]

M. Uplekar, D. Weil, K Lonnroth, et al., WHO's new end TB strategy. Lancet, 2015, 385: 1799-1801.

[7]

J. H. Joncas, R. Robitaille, and T. Gauthier, Interpretation of the PPD skin test in BCG-vaccinated children. Can Med Assoc J, 1975, 113: 127-128.

[8]

M. Farhat, C. Greenaway, M. Pai, et al., False-positive tuberculin skin tests: What is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis, 2006, 10: 1192-1204.

[9]

R.E. Watkins, R. Brennan, and A.J. Plant, Tuberculin reactivity and the risk of tuberculosis: A review. Int J Tuberc Lung Dis, 2000, 4: 895-903.

[10]

F. Deck, J. Guld, The WHO tuberculin test. Bull Int Union Tuberc, 1964, 34: 53-70.

[11]
American Thoracic Society, Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep, 2000, 49: 1-51.
[12]

M. Pai, C. M, Denkinger, S.V. Kik, et al., Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev, 2014, 27: 3-20.

[13]

V. Herrera, S. Perry, J. Parsonnet, et al., Clinical application and limitations of interferon-gamma release assays for the diagnosis of latent tuberculosis infection. Clin Infect Dis, 2011, 52: 1031-1037.

[14]
P.Q. Edwards, L.B. Edwads, Story of the tuberculin test from an epidemiologic viewpoint. Am Rev Respir Dis, 1960, 81(1) Pt 2: 1-47.
[15]

R.T. Horvat, Gamma interferon assays used in the diagnosis of tuberculosis. Clin Vaccine Immunol, 2015, 22: 845-849.

[16]

O. Manuel, D. Kumar, QuantiFERON-TB gold assay for the diagnosis of latent tuberculosis infection. Expert Rev Mol Diagn, 2008, 8: 247-256.

[17]

A. Lalvani, Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest, 2007, 131: 1898-1906.

[18]

G.H. Mazurek, J Jereb, A. Vernon, et al., Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep, 2010, 59: 1-25.

[19]

C. M Denkinger, K. Dheda, and M. Pai, Guidelines on interferon-gamma release assays for tuberculosis infection: concordance, discordance or confusion? Clin Microbiol Infect, 2011, 17: 806-814.

[20]

H.R. Mujakperuo, R.D. Thompson, and D.R. Thickett, Interferon gamma release assays and the NICE 2011 guidelines on the diagnosis of latent tuberculosis. Clinical Medical, 2013, 13: 362-366.

[21]

M.J. Fenton, M.W. Vermeulen, S. Kim, et al., Induction of gamma interferon production in human alveolar macrophages by Mycobacterium tuberculosis. Infect Immun, 1997, 65: 5149-5156.

[22]

A.M. Gallegos, J.W. van Heijst, M. Samstein, et al., A gamma interferon independent mechanism of CD4 T cell mediated control of M. tuberculosis infection in vivo. PLoS Pathog, 2011, 7: e1002052.

[23]

P. Andersen, M.E. Munk, J.M. Pollock, et al., Specific immune-based diagnosis of tuberculosis. Lancet, 2000, 356: 1099-1104.

[24]

G.H. Mazurek, J. Jereb, P. Lobue, et al., Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. , 2005, 54: 49-55.

[25]

M. Bocchino, B. Bellofiore, A. Matarese, et al., IFN-gamma release assays in tuberculosis management in selected high-risk populations. Expert Rev Mol Diagn, 2009, 9: 165-177.

[26]

G. Ferrara, M. Losi, R.D. Amico, et al., Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: A prospective study. Lancet, 2006, 367: 1328-1334.

[27]

M.G. Madariaga, Z. Jalali, and S. Swindells, Clinical utility of interferon gamma assay in the diagnosis of tuberculosis. J Am Board Fam Med, 2007, 20: 540-547.

[28]

Y. Dai, Y. Feng, R. Xu, et al., Evaluation of interferon-gamma release assays for the diagnosis of tuberculosis: an updated meta-analysis. Eur J Clin Microbiol Infect Dis, 2012, 31: 3127-3137.

[29]

G. Redelman-Sidi, K.A. Sepkowitz, IFN-gamma release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med, 2013, 188: 422-431.

[30]

M. Sester, G. Sotgiu, C. Lange, et al., Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J, 2011, 37: 100-111.

[31]

A. Kowada, Cost-effectiveness of interferon-gamma release assay for entry tuberculosis screening in prisons. Epidemiol Infect, 2013, 141: 2224-2234.

[32]

M. Pareek, M. Bond, J. Shorey, et al., Community-based evaluation of immigrant tuberculosis screening using interferon gamma release assays and tuberculin skin testing: Observational study and economic analysis. Thorax, 2013, 68: 230-239.

[33]

A.N. Aggarwal, R. Agarwal, D. Gupta, et al., Interferon gamma release assays for diagnosis of pleural tuberculosis: a systematic review and meta-analysis. J Clin Microbiol, 2015, 53: 2451-2459.

[34]

Q.L. Liang, H.Z. Shi, K. Wang, et al., Diagnostic accuracy of adenosine deaminase in tuberculous pleurisy: A meta-analysis. Respir Med, 2008, 102: 744-754.

[35]

J. Klimiuk, R. Krenke, Role of biomarkers in making the diagnosis of tuberculous pleurisy. Pneumonol Alergol Pol, 2011, 79: 288-297.

[36]

C. Liu, Z. Zhao, J. Fan, et al., Quantification of circulating Mycobacterium tuberculosis antigen peptides allows rapid diagnosis of active disease and treatment monitoring. Proc Natl Acad Sci U S A, 2017, 114: 3969-3974.

[37]

C.C. Lai, C.K. Tan, C.H. Chou, et al., Increasing incidence of nontuberculous mycobacteria. Taiwan, 2000-2008. Emerg Infect Dis. , 2010, 16: 294-296.

[38]

V.A. Simossis, J. Heringa, The PRALINE online server: optimising progressive multiple alignment on the web. Comput Biol Chem, 2003, 27: 511-519.

[39]

J. van Ingen, R. de Zwaan, R. Dekhuijzen, et al., Region of difference 1 in nontuberculous Mycobacterium species adds a phylogenetic and taxonomical character. J Bacteriol, 2009, 191: 5865-5867.

[40]

W. Sun, S. Gao, L. Wang, et al., Microwave-assisted protein preparation and enzymatic digestion in proteomics. Mol Cell Proteomics, 2006, 5: 769-776.

[41]

R. Patel, MALDI-TOF mass spectrometry: Transformative proteomics for clinical microbiology. Clin Chem, 2013, 59: 340-342.

[42]

C.M. Denkinger, J. Grenier, J. Minion, et al., Promise versus reality: optimism bias in package inserts for tuberculosis diagnostics. J Clin Microbiol, 2012, 50: 2455-2461.

[43]

A. Muller, H. Bogge, F.L. Sousa, et al., Nanometer-sized molybdenum-iron oxide capsule-surface modifications: External and internal. Small, 2007, 3: 986-992.

[44]
G. Kim, R. O'regan, and S. Nie, Biomedical nanotechnology for molecular imaging, profiling and drug targeting. Proceedings of the 27th Annual International Conference of the Engineering in Medicine and Biology Society. Shanghai, China, Jan. 17-18, 2005: 714-716.
[45]

C. Lang, D. Schulaer, and D. Faivre, Synthesis of magnetic nanoparticles for bio- and nanotechnology: genetic engineering and biomimetics of bacterial magnetosames. Macromol Biosci, 2007, 7: 144-151.

[46]

T.T. Feng, C.M. Shou, L. Shen, et al., Novel monoclonal antibodies to ESAT-6 and CFP-10 antigens for ELISA-based diagnosis of pleural tuberculosis. Int J Tuberc Lung Dis, 2011, 15: 804-810.

[47]

S.M. Arend, K.E. van Meijgaarden, K. de Boer, et al., Tuberculin skin testing and in vitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M. kansasii. J Infect Dis, 2002, 186: 1797-1807.

[48]

E.S. Hesham, A. Asma, A.T. Mohamed, et al., Nanodiagnostics for tuberculosis detection. Expert Review of Molecular Diagnostics, 2017, 5: 427-443.

Nano Biomedicine and Engineering
Pages 79-86
Cite this article:
Chen X, Wang K, Li H, et al. Current Status and Progress of Specific Laboratory Examination Methods of Active Tuberculosis Infection Diagnosis. Nano Biomedicine and Engineering, 2018, 10(1): 79-86. https://doi.org/10.5101/nbe.v10i1.p79-86

499

Views

10

Downloads

1

Crossref

1

Scopus

Altmetrics

Received: 08 November 2017
Accepted: 28 March 2018
Published: 30 March 2018
© Xuyang Chen, Kan Wang, Hongying Li, Lixin Hong, and Jinghua He.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Return